Invivyd, Inc. (Nasdaq: IVVD) creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, drug and adapt to create best in class antibodies.
| Website | http://www.invivyd.com |
| Employees | 177 (145 on RocketReach) |
| Founded | 2020 |
| Address | 209 Church St, New Haven, Connecticut 06510, US |
| Phone | +1 214-999-9999 |
| Industry | Biotechnology Research |
| Keywords | Viral Vectors, Biopharmaceutical, Rna Therapeutics, Predictive Modeling, Antiviral Therapies, Immunology, Vaccine Development, Infectious Disease Research, Drug Development, Biotechnology, Pharmaceutical Research, Clinical Trials, Therapeutics, Immunotherapies, Public Health, Global Health, Infectious Disease Control, Pandemic Preparedness |
| Competitors | Johnson & Johnson, Roche, Merck & Co., Inc., Pfizer, Sanofi, AstraZeneca, Regeneron, Moderna Therapeutics, Novavax, Zymergen, Inc. +34 more (view full list) |
Looking for a particular Invivyd employee's phone or email?
William Duke is the CFO of Invivyd.
145 people are employed at Invivyd.
Invivyd is based in New Haven, Connecticut.